Genmab, Seattle Genetics to start Phase II of tisotumab vedotin in cervical cancer

Genmab A/S (CSE:GEN; Pink:GMXAY) and Seattle Genetics Inc. (NASDAQ:SGEN) plan to begin a single-arm

Read the full 140 word article

User Sign In